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Unravellingthemolecularmechanismsunderlyinggastriccarcinogenesisisoneofthemajorchallengesincancergenomics.Gastric
cancer is a very complex and heterogeneous disease, and although much has been learned about the diﬀerent genetic changes that
eventually lead to its development, the detailed mechanisms still remain unclear. Malignant transformation of gastric cells is the
consequenceofamultistepprocessinvolvingdiﬀerentgeneticandepigeneticchangesinnumerousgenesincombinationwithhost
genetic background and environmental factors. The majority of gastric adenocarcinomas are characterized by genetic instability,
either microsatellite instability (MSI) or chromosomal instability (CIN). It is believed that chromosome destabilizations occur
early in tumour progression. This review summarizes the most common genetic alterations leading to instability in sporadic
gastric cancers and its consequences.
1.Introduction
Gastric cancer remains a worldwide burden as one of the
leading causes of cancer-related death in both sexes [1–3].
The late onset of clinical symptoms is the main reason that
the disease is often diagnosed at an advanced stage, which
limits available therapeutic approaches in more than 50% of
cases [2–5]. Although extensive studies have been performed
toidentifygeneticpathwaysandgenesinvolvedinthedisease
development and progression, the prognosis for patients
with gastric cancer remains poor and little improvement of
long-term survival has been achieved [6].
Adenocarcinoma is the major histological type of gastric
cancer, accounting for 90% to 95% of all gastric mali-
gnancies. Based on the Lauren classiﬁcation, which is mainly
used in clinical setting, adenocarcinomas are divided into
twodistinctpathologicalentities,intestinalanddiﬀusetypes,
which have diﬀerent clinicopathological and prognostic
features [3]. Intestinal type is associated with Helicobacter
pylori infection, obesity, and certain dietary factors, such as
high intake of salt, smoked meats, and food preserved with
nitrites or nitrates, and is believed to arise through a long-
term multistep progression from chronic gastritis to chronic
atrophy to intestinal metaplasia to dysplasia [3, 7, 8]. Histo-
logically it is well diﬀerentiated and occurs more commonly
in older patients [7]. Diﬀu s et y p ei sp o o r l yd i ﬀerentiated
with inﬁltrating, noncohesive cells and is more frequent in
younger patients [7, 9]. Studies showed that Helicobacter
pyloriinfectionalsoplaysaroleinthedevelopmentofdiﬀuse
gastric cancer, through chronic inﬂammation, but without
occurrence of intermediate steps, such as gastric atrophy and
intestinal metaplasia [10].
During the last few decades the studies of gastric cancer
showed that it results from the complex gene-environment
interactions [9]. New high-throughput techniques have
revealed its heterogeneous milieu with alterations of many
genes, deregulation of signalling pathways, aberrant DNA
methylation patterns, and chromosomal imbalances. Never-
theless, there is still no clear agreement on the genetic and
epigenetic changes underlying the initiation and progression
of gastric adenocarcinoma [9, 10]. Furthermore, it is evident
that DNA polymorphisms along with individual’s immune
function and environmental factors contribute to the disease
[10]. Even more, the biological characteristics of gastric
tumours vary from case to case, and tumours from one
individualarecomprisedofmalignantcellsshowingdiﬀerent
characteristics, growth preferences, and expression patterns
[11]. Due to these facts and aggressive behaviour of most
subtypes of gastric adenocarcinomas, it is diﬃcult to choose
the optimal therapeutic approach.2 The Scientiﬁc World Journal
This paper is intended to focus on most common genetic
aspects of genomic instability in gastric carcinogenesis and
presents the current knowledge on some of the mechanisms
and molecular pathways of malignant transformation.
2. Chromosomal Instability(CIN)
Chromosomal instability (CIN) is the most common type of
genomic instability observed in solid tumours [5, 12]. CIN
is characterized by gross chromosomal abnormalities, such
as gain or loss of whole chromosomes (aneuploidy) and/or
fractions of chromosomes (loss of heterozygosity (LOH),
ampliﬁcations, and translocations) [13]. These alterations
could also aﬀect the expression of oncogenes, tumour
suppressor genes, and other genes, such as genes implicated
in digestion, DNA repair genes (genome stability genes),
growth regulators, and cell cycle checkpoint control genes,
and so CIN has been detected as the most common feature
of sporadic gastric cancers and has been reported in up to
84% of gastrointestinal tumours [5, 14]. Numerous DNA
copy number variations have been reported, and subgroups
with diﬀerent patterns of DNA copy number alterations
have been recognized, which have been associated with age,
prognosis, lymph node status, and metastasis [9, 11, 15–
18]. Buﬀart et al. explored comparative genomic hybridis-
ation (CGH) proﬁles of gastric adenocarcinomas in young
and old patients [19]. They found out that chromosome
regions 11q23.3 and 19p13.3 contributed most to age-related
diﬀerences in tumour proﬁles and that tumours of younger
patients showed gains in chromosomal regions 6p21, 9p34,
11p15, 11q23, 17p13, 19p13, and 22q13, whereas in the
majority of older patients normal copy status was observed.
These diﬀerences in genomic proﬁles likely reﬂect diﬀerent
pathogenic mechanisms of the disease. Varis et al. similarly
observed that the most frequent cytogenetic aberrations
were gains seen at 17q, 19q, and 20q in younger patients
[20]. Furthermore, in another study, Buﬀart et al. showed
that gastric cancers from South African and UK patients
diﬀer in genetic instability patterns, indicating possible
diﬀerent biological mechanisms of carcinogenesis in patients
from diﬀerent geographical origin [12]. Their results also
revealed that South African patients showed signiﬁcantly
more microsatellite instable gastric cancers compared to
Western European patients. Tsukamoto et al. also observed
high frequencies of DNA copy number aberrations; for
example, the 20q13 chromosome gain was detected in 97%
of cases [21]. They used laser microdissection method to
isolate tumour cells; therefore, their samples contained less
cells from tumour microenvironment. They also identiﬁed
114 upregulated candidate genes located in regions of
ampliﬁcation and 11 downregulated genes located in regions
of deletion.
LOH is also a marker of chromosomal instability and
might indicate a second inactivation hit of cancer suppressor
genes. Several LOH studies demonstrated that the extent of
chromosomal loss appeared to be of prognostic signiﬁcance
[22–24]. We and other researches showed that two distinct
subtypes, high-level LOH (named LOH-H) and low-level
LOH (named LOH-L), could be correlated with intestinal
or mixed and diﬀuse growth patterns, respectively [23,
25]. LOH has been shown to relate to cancer progression,
where a transition from LOH-L to LOH-H is thought to
reﬂectanincreaseinchromosomalinstabilityduringtumour
advancement. We also found that the highest frequency of
LOH was at APC locus (36%), followed by TP53-1 (33%),
nm23 (33%), TP53-2 (24%), and RB (24%) [23]. Recently,
Karaman et al. found signiﬁcant correlation between preva-
lence of 17p (TP53) LOH in gastric precancerous lesions,
indicating that loss of TP53 could be an early event in gastric
carcinogenesis [26]. The highest LOH frequencies have been
identiﬁed at 1p, 2q, 3p, 4p, 5q, 6p, 7p, 7q, 8p, 9p, 11q,
12q, 13q, 14q, 17p, 18q, 21q, and 22q chromosome regions
in gastric carcinomas [9, 27]. The main consequence of
LOH is loss of genes, such as tumour suppressors, cell cycle
regulators, DNA repair genes, and other genes implicated in
the maintenance of cell cycle and/or integrity of DNA.
The genetic mechanisms leading to CIN are largely
unknown. It has been suggested that chromosome segrega-
tion defects, defective DNA damage response, aberrations in
cell cycle regulators, and telomere dysfunction could lead
to numerical and structural chromosome alterations [28,
29]. Furthermore, carcinogens such as Helicobacter pylori
infection, tobacco, nitrates, and nitrites have an important
impact on chromosomal stability in genetically susceptible
individuals [4]. Chemical and physical carcinogens induce
the malignant transformation by altering either chromo-
somes or the spindle apparatus by disrupting microtubules
[30–32]. Certain carcinogens, such as tobacco, also reduce
antioxidant capabilities and enhance lipid peroxidation and
oxidant-mediated tissue damage, thus increasing the risk of
gastric cancer [33].
2.1. Chromosome Segregation Dysfunction Leading to Chro-
mosome Instability. Segregation is one of the fundamental
processes in cells, which are rapidly dividing, such as
gastric epithelial cells. Therefore, if regulation mechanisms,
governing this process are damaged, the cells might proceed
through cytokinesis with DNA or spindle errors and could
inheritunrepairedmutationsorgainanabnormalnumberof
chromosomes [34]. However, the molecular defects underly-
ing CIN and whether it is a cause or consequence of tumour
phenotype are not completely clear. At least three possible
mechanisms for CIN development have been suggested:
aberrant expression, mutations and/or polymorphisms in
mitotic genes, implicated in chromosome segregation, or the
activity of carcinogens on susceptible genetic background
of individuals [35, 36]. Several studies presented evidence
that altered expression of mitotic genes could aﬀect chro-
mosome segregation. For example, Grabsch et al. observed
overexpression of BUB1 protein in gastric cancers, which
was signiﬁcantly higher in tissues of patients with diﬀuse-
type adenocarcinomas [14]. However, their study did not
reveal any association between BUB1 protein expression
level and DNA ploidy status of examined tumour types.
BUB1 along with BUBR1, Aurora kinase B (AURKB), TTK,
and other proteins is implicated in controlling the spindle
assembly checkpoint. Ando et al., on the other hand, found
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and DNA aneuploidy [37]. Interestingly, in another study
investigating the expression status of BUBR1 and AURKB,
the authors concluded that overexpression of BubR1 and
AURKB is associated with a low risk of gastric cancer
progression [38]. MAD1 and MAD2 are also important
regulators of cell cycle progression, involved in alignment
of chromosomes at the metaphase plate. Studies suggested
that MAD1 and MAD2 could be tumour suppressor genes,
based on their reduced expression in gastric carcinomas
[39, 40]. Aurora kinase A (AURKA or STK15) located at
20q13, a region that is frequently ampliﬁed in gastric cancer,
has been found overexpressed in stomach adenocarcinomas
[41]. AURKA is a cell-cycle-regulated kinase that appears to
be involved in microtubule formation and/or stabilization
at the spindle pole during chromosome segregation, thus
ensuring equal partition of replicated chromosomes to
daughter cells. Functional analysis of upregulated AURKA
gene revealed a possible novel oncogenic pathway, involved
in gastric carcinogenesis. AURKA overexpression led to a
signiﬁcant increase in mRNA levels of several direct targets
of the β-catenin/TCF transcription complex (cyclin D1, c-
MYC, c-MYC binding protein, CLDN1, FGF18, and VEGF)
[42]. It was shown that AURKA overexpression overrides
the mitotic spindle checkpoint and leads to incomplete
cytokinesis, multinucleation, and multipolar spindles [43,
44]. Other important regulators of cell cycle progression,
such as CCNB1, CCNE1, PTTG1, and PLK, have also been
found overexpressed in gastric carcinomas and associated
with poor prognosis [45–48].
Studies on several animal species and humans showed
that certain genetic alterations and mutations in segregation
genes might cause an increased incidence of a particular
tumour type [49, 50]. However, these and several other
studies explored overexpression and/or mutations of these
genes, which could already be the consequence of CIN.
Therefore, it has been proposed that minor alterations
in mitotic genes could contribute to the onset of cancer
[51]. High-throughput genotyping is suggesting that subtle
variations, such as polymorphisms or nonlethal mutations,
might induce CIN and aneuploidy. This hypothesis of
low-penetrance allelic variants or risk alleles is further
supported by the late onset of nonheritable cancers, whereas
dominant mutations in oncogenes and tumour suppressors
usually induce the disease early in life [31, 51]. Genetic
variants inmitotic genesincombinationwithenvironmental
factors could modulate mitotic pathways, thus causing slow
accumulation of chromosomal aberrations in replicating
epithelial cells. The key turnaround in this process is the
impairment of critical oncogenes and tumour suppressors
which enable uncontrolled proliferation and growth of cells.
The search for “driving” alterations in these low-penetrance
genes has begun only recently, and further investigations on
larger cohorts are needed to establish the biological basis for
the role of risk alleles of mitotic genes and their involvement
in gastric carcinogenesis.
2.2.DefectiveDNADamageResponse. Cellsofgastricmucosa
are constantly exposed to diﬀerent environmental and intra-
cellular mutagens, such as naturally occurring reactive oxy-
gen and nitric oxide species (RONS), Helicobacter pylori
infection (discussed below), natrium (salt), nitrates, nitrites,
and other environmental contaminants in water and food.
These mutagens have been shown to induce DNA damage
through diﬀerent mechanisms [4, 6]. The main DNA repair
pathways, responsible for maintaining the integrity of gastric
cell genome, are base excision repair (BER) for repair of
endogenous/oxidative damage, nucleotide excision repair
(NER) for adducts, mismatch repair (MMR) for single-
nucleotide mismatches and DNA polymerase slippage, and
recombination and/or DNA damage response (DDR) for
repairing double-strand breaks [52, 53]. Failure of these
pathways can lead to chromosomal instability and/or to
accumulation of genetic alterations, which favour neoplastic
transformation. Guo et al. studied the phosphoproteome
and transcriptome of gastric cancer cell lines and tissues of
gastric cancer patients, patients with gastritis, and normal
subjects. Using a combined approach with LC-MS/MS-
based and protein antibody arrays, they established that
DDR pathway appears overrepresented in investigated spec-
imens (overexpressed MRE11, RAD1, RAD9, CHK2, and
p53 proteins). Several studies also revealed diﬀerentially
expressed mRNA of genes, involved in diﬀerent DNA repair
mechanism, such as ATM (involved in BER), HMGB1
(involved in BER), RAD23B (involved in NER), UBE2V2,
MUS81 (involved in resolving Holliday junctions), REV3L
(implicated in translesion replication after DNA damage),
TP53,hHR23A(involvedinNER),DDB1(involvedinNER),
and XRCC1 (involved in repair of single-strand breaks),
MUTYH (involved in BER) [45, 54–58].
It is also very likely that inherited polymorphisms in
DNA repair genes could inﬂuence the host ability to detect
and repair DNA damage in the presence of the permissive
microenvironment [53]. Palli et al. investigated the eﬀect of
selected polymorphism in DNA repair genes alone and in
combination with polymorphisms in GST genes, involved in
ROS detoxiﬁcation, on gastric cancer risk [53]. They found
a borderline association between XPC-PAT+/+ genotype
and increased risk for the development of gastric cancer.
However, when they explored gene-gene interactions, they
observed signiﬁcant interactions between polymorphisms
in DNA repair genes and also in interactions between
DNA repair polymorphisms in combination with GST poly-
morphisms. For instance, the interactions between DNA
repair gene polymorphisms APE1-D148E (BER) and XPA-
23G>A (NER), and between XPC-PAT (NER) and XPA-
23G>A (NER), showed a high association. A signiﬁcant
association was also conﬁrmed between APE1-D148E (BER)
and GSTT1 and between APE1-D148E (BER) and GSTM1-
GSTT1 double-null genotype. The authors did not ﬁnd
signiﬁcant associations between selected polymorphisms in
other DNA repair genes, such as OGG1 (BER), XRCC1
(BER), XPD (NER); XRCC3 (NER), ERCC1 (NER), MGMT
(NER). However, the homozygous carriers of W allele of
this XRCC1 polymorphism (R194W) were highly associ-
ated with increased gastric cancer risk in Chinese and
Japanese populations [59–61]. Several other polymorphisms
in diﬀerent DNA repair genes have been extensively studied
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cancer risk in diﬀerent populations [62–67]. It is believed
that inconsistency of these reports could underlie diﬀer-
ences in ethnicity, lifestyle, and disease prevalence [53].
Furthermore, only a few studies addressed the additive
eﬀect of these polymorphisms alone or in combination
with polymorphisms in other genes on gastric cancer risk.
There is also a lack of studies on their interactions and
biological behaviour in combination with diﬀerent environ-
mental triggers. Altered function of these low-penetrance
genes due to polymorphisms may aﬀect gene-environment
and gene-gene interactions, thus favouring slow neoplastic
transformation, which is characteristic for sporadic gastric
cancers. In addition to aﬀecting gastric cancer risk, inherited
polymorphisms are also associated with eﬃcacy and toxicity
of chemotherapeutics [68].
2.3. Helicobacter-pylori-Induced Chromosome Instability. It
has been shown that Helicobacter pylori triggers DNA
double-strand breaks and DNA damage response (DDR)
in cultured gastric adenocarcinoma and murine primary
gastric epithelial cells in a process that probably requires
adhesion of viable bacteria through interaction of BabA
adhesin and host’s Lewis epitopes [69]. In addition, Toller
et al. also assessed the ability of cultured cells to repair
the fragmented DNA. They observed that after short-
term infection of gastric cells the cells retain their ability
to repair double-strand breaks, while prolonged infection
leads to elevated cell lethality, probably through saturation
of repair mechanisms. The overloaded repair machinery
(or ineﬃciency of repair proteins due to other mutations
and/or polymorphisms) could cause ineﬃcient and muta-
genic double-strand break repair, thus inducing carcinogenic
transformation. Furthermore, persistent infection with Heli-
cobacter pylori initiates chronic inﬂammation, which induces
increased tissue turn-over, increased rate of mutagenesis,
oxidative-stress-related changes in proteome, downregula-
tion of base excision and mismatch repair mechanisms, and
genetic instability, and modulates apoptosis through the
generation of reactive oxygen and nitrogen species (RONS)
[10, 70–74]. Speciﬁcally, generation of RONS, produced by
recruited immune cells to the site of inﬂammation, has been
associated with oxidative DNA damage, DNA single-strand
breaks, crosslinking of DNA, direct mutation of TP53 gene,
protein damage by nitrosylation, inhibition of apoptosis by
nitrosylation of caspases, and promotion of angiogenesis
[75, 76]. Furthermore, host genetic background also plays an
important role in Helicobacter-pylori-induced gastric cancer.
Increased risk of cancer development in individuals infected
with this bacteria has been associated with polymorphisms
in genes implicated in gastric acid secretion, immune
response, adhesion to epithelial cells, and other biological
functions [4]. For example, it has been reported that a
combination of polymorphisms within proinﬂammatory
genes IL-1β, IL-1RA, TNFα, and IL-10 conferred greater
risk for gastric cancer development in combination with
Helicobacter pylori infection [77, 78]. Although the exact
mechanisms of Helicobacter-pylori-induced carcinogenesis
are not yet elucidated, it is believed that the combination
of microenvironment, virulent microorganism, persistent
inﬂammation response, and a genetically susceptible host
drives the process of gastric cell transformation [79].
3.MicrosatelliteInstability(MSI)
Another type of genomic instability, commonly recognized
in gastric cancer, is microsatellite instability (MSI). Studies
showed that MSI is characteristic for hereditary type of gas-
tric cancer, developed in the context of the Lynch syndrome,
and a smaller subset of sporadic cancers ranging from 25%
to 50% [5]. Patients with MSI phenotype exhibit a high fre-
quency of replication errors resulting in insertions/deletions
of nucleotides within microsatellite repeats in tumour tissues
[5] .T h e s ee r r o r sa r ed e t e c t e da n dr e p a i r e db yac o m p l e x
of mismatch repair (MMR) proteins [78]. Inactivation or
deﬁciency of one or more MMR genes, particularly MLH1 or
MSH2, induces development of MSI phenotype, which often
leads to additional genetic changes, namely inactivation of
tumour suppressor genes and LOH [80, 81]. Impairment of
MMR can occur (1) by mutational inactivation of one or two
MMR genes or (2) by epigenetic inactivation of MMR genes
(CpG island methylator pathway, CIMP). In gastric cancer,
functional inactivation of MMR is mainly caused by latter.
Epigenetic hypermethylation of MLH1 promoter has been
found to be responsible for the development of more than
50% MSI-H-positive gastric cancers, whereas mutations in
MLH1 and MSH2 are being reported in 12–15% of gastric
cancers exhibiting MSI-H phenotype [82–85]. Genomes
of gastric cancers exhibiting MSI are characterized by the
presence of multiple frameshift mutations in many genes at
variable frequencies [2]. Genes that were frequently found to
be altered as a consequence of impaired MMR are implicated
in cell cycle regulation and apoptosis (TGFβ RII, IGFIIR,
TCF4, RIZ, BAX, CASPASE5, FAS, BCL10, and APAF1)
or are involved in genomic integrity maintenance (MSH6,
MSH3,MED1,RAD50,BLM,ATR,andMRE11)[5,86].The
alterations in these genes further promote genetic instability
and enhance the development of malignant phenotype.
4. Deregulationof SignallingPathways
The pathogenic mechanisms inducing genome instability
could be responsible for deregulation of signalling pathways
implicated in gastric homeostasis (Figure 1). The main con-
sequences of genomic destabilization are aneuploidy, gains
and losses of chromosome regions, resulting in ampliﬁcation
of oncogenes and/or LOH; translocations, inversions, and
accumulation of point mutations, insertions, and deletions
in coding sequences, regulatory sequences, and noncoding
sequences,implicatedinprocessingofmRNAtranscripts.All
these changes aﬀectnormal biological behaviour of cells, and
certain combinations of changes induce the development
and establishment of proliferating, invasive cell populations,
which formthe tumour mass. The malignant cells inherit the
driving genetic mutations and/or polymorphisms implicated
in instability generation; therefore, the process of genomic
destabilization continues, explaining the heterogeneity of
gastric tumours.The Scientiﬁc World Journal 5
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Figure 1: The pathogenic mechanisms inducing CIN or MSI lead to gastric cancer development.
Withthedevelopmentofnewhigh-throughputmethods,
it became evident that aberrations of certain signalling path-
ways could be important in gastric carcinogenesis. Further-
more,amultitudeofgeneticchangesfoundingastriccancers
implies that many of the changes aﬀecting the pathways
could be individual; for example, patients could have diﬀer-
ent genes aﬀected within the pathway, but resulting in the
same ﬁnal eﬀect-deregulated pathway driving and sustaining
neoplastic cells.Someofthesepathwayswereinitiallydiscov-
ered to be active during embryogenesis, but recent research
showed that they are also involved in regeneration process of
g a s t r i cm u c o s a[ 87]. As expected, global expression analyses
showed aberrant expression of many genes, which diﬀer
among individuals, but are implicated in the same signalling
networks [45, 87–91]. Furthermore, there is a complex in-
terplay between environmental factors and these pathways
that remains to be elucidated. The most studied pathways
that likely contribute to gastric pathogenesis are Wnt/beta-
catenin, extracellular signal-regulated MAPK, Hedgehog,
Notch, COX2/PGE2, NF-κB, TGF-β/BMP pathways, and
tyrosine kinase signalling [45, 92–113]. The molecular
mechanisms underlying the oncogenic signalling of these
pathways have been extensively reviewed before [10, 91,
114]. Recent studies revealed that deregulation of pathways
implicated in systemic inﬂammatory response, for example,
IL-11/gp130/STAT1/STAT3, could also encourage malignant
transformation[115–117].Inagp130(Y757F/Y757F)mouse
model of gastric cancer, it was demonstrated that mutated
gp130 activates STAT3, resulting in downstream activation
of inhibitory protein SMAD7, which blocks stromal TGF-
β signalling, thus suppressing the cytostatic eﬀect of sur-
rounding stromal cells on tumour cell proliferation. Stat3
could also enhance oncogenic signalling by inducing IL-11
expression, which activates mutated gp130, further promot-
ing the signalling cycle and proliferation of aberrant cells.
[115]. Additionally, gp130 also activates JAK/STAT and SHP-
2/ras/MAPK/ERK1-2/AP-1 signalling cascades, resulting in
the suppression of TFF1 tumour suppressor gene, and
concomitant STAT3 activation results in mucosal atrophy,
metaplasia, cellular proliferation, dysplasia, and submucosal
invasion [118]. Another well-characterized genetic model
of gastric carcinogenesis includes inactivation of RUNX3, a
downstream target of TGB-β signalling pathway, resulting in
thesuppressionoftheapoptosisingastrictumourcells[119].
Additionally, it should be noted that many of these pathways
converge and that individually diﬀerent combinations of
aberrations in genes implicated in these signalling networks
encourage or deter cancer development. Deﬁning which
pathways and how they are aﬀected in individual patients
couldbeofimportanceforthediagnosisandfordetermining
the potential targets for cancer treatment.
5. Conclusion
Several other pathways leading to chromosomal instability in
gastric cancers exist, which were not discussed, for example,6 The Scientiﬁc World Journal
telomere shortening, telomerase activation, relaxation of
cell-cycle checkpoints, incomplete chromosomal replication,
and so forth [29, 120]. The complexity and heterogeneity
of gastric tumours provide evidence that gastric cancer is
the consequence of a multistep process involving diﬀerent
genetic and epigenetic changes in numerous genes in com-
bination with host genetic background and environmental
factors. The number of altered genes implicated in gastric
carcinogenesis is immense, and the importance of these
changes is not clear [10]. Genetic instability plays an
important role in neoplastic initiation and progression,
and according to research, is an early event in gastric car-
cinogenesis. However, exact driving factors responsible for
genome destabilization have not yet been found. In addition,
complex gene-gene interactions, gene-environment interac-
tions,lifestyle,andethnicbackgroundfurthercomplicatethe
elucidation of gastric pathogenesis. Complete genotyping of
gastric cancer patients could oﬀer a better insight in genetic
polymorphisms and their interactions, thus enabling the
isolation of populations with increased risk for the disease
development. There is also a need to develop algorithms that
couldexplainallthesechangesfoundinindividualsandtheir
interactions. Furthermore, it is necessary to perform large
studies and meta-analyses to deﬁne panels of biomarkers for
determination of susceptibility, for diagnosis, prognosis, and
treatment.
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